Barely Significant

Excerpts

514,629 sentences

highly significantp < 0.0010.0× alphaqualifiedgold
Regarding geographical location differences, Chi-square analysis revealed a highly significant difference between youths’ responses ( χ 2 2 = 15.537, p < 0.001): 25.70% of urban youths perceived aesthetic qualities in their neighbourhood, whereas 10.78% of rural farm youths and 9.57% of rural desert youths perceived aesthetic qualities in their neighbourhood.
highly significantp <.0010.0× alphaqualifiedgold
A highly significant effect of Change was observed, F (1, 68) = 15.31, p <.001, η 2 p =.18, indicating faster responses when color was repeated (M = 863.92, SD = 79.72) compared with when changed (M = 877.85, SD = 79.617), and neither significant effects of Preceding Distractor Value, F (2,136) = 2.16, p =.119, η 2 p =.03, nor a significant interaction, F (2,136) =.54, p =.581, η 2 p <.01.
highly significantP < 0.0010.0× alphaqualifiedgold
As shown in Figs 4 C,D and 5 out of 18 hits, represented by dexamethasone, flumethazone, colchicine, thimerosal, and doxorubicin displayed highly significant effect (P < 0.001) at 1 μM; 4 out of them, i.e. colistimetate, megestrol, melphalan, and metronidazole showed a significant effect (P < 0.05) at 1 μM; while cyproterone and nitrofurantoin compounds displayed a slight dose-response trend at the doses used, accounting for a total of 11 compounds (61%) globally validating approximately 0.5% of hits from the primary screening.
highly significantP < 0.0010.0× alphaqualifiedgold
Sushruta and Charaka contributed separate chapter on Arsha and included in the list of grave disease.[ 7 , 8 ] After AKA, bleeding per rectum stopped completely in second week while after SCL, bleeding per rectum completely stopped in 3 rd week [ Table 2 ], which was highly significant ( P < 0.001) [ Table 3 ].
highly significantP < 0.0010.0× alphaqualifiedgold
The published results showed that, compared with placebo, everolimus showed a highly significant improvement in radiologically defined PFS using both investigator (6.9 vs. 2.8 months, hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.35-0.54; P < 0.001) and independent reviewers’ assessment (10.6 vs. 4.1 months, HR = 0.36; 95% CI, 0.27-0.47; P < 0.001).[ 2 ] Based on these data, the US FDA approved everolimus for the treatment of appropriately selected postmenopausal women with advanced breast cancer.
Progression-free or overall survival…revisited in BOLERO-2.
Indian J Med Paediatr Oncol · 2014 · PMC4080643